Lakhasly

S.A. Berry, C. Brown, M. Grant, C.L. Greene, E. Jurecki Newborn screening 50 years later: access issues faced by adults with PKU Genet. Med., 15 (2013), pp. 591-599(1).
(introduction)

Palermo, L., Geberhiwot, T., MacDonald, A., Limback, E., Hall, S. K., & Romani, C. (2017). Cognitive outcomes in early-treated adults with phenylketonuria (PKU): A comprehensive picture across domains. Neuropsychology, 31(3), 255-267(2).
(intoduction)

incednt
William L. Stone; phenylketonuria,2019, pubmed from https://www.ncbi.nlm.nih.gov/books/NBK535378(3).
​ Ashraf El metwaly, The Prevalence of Phenylketonuria in Arab Countries, Turkey, and Iran: A Systematic Review,2018 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932526(4).
​.(5) Robin Wallims, Phenylketonuria: An Inborn Error of Phenylalanine Metabolism,2008 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423317

Naz Al Hafid Phenylketonuria: a review of current and future treatments,2015 from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728993 (6)./
Symptoms
Blau N. Genetics of Phenylketonuria: Then and Now. Hum Mutat. 2016 Jun;37(6):508-15. doi: 10.1002/humu.22980. Epub 2016 Mar 18. Review. Citation on PubMed(7).

diagnosis

. (8) Blau NT, Cotton RG, Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, editor. The Metabolic and Molecular Bases of Inherited Disease. New York: McGraw Hill; 2001. pp. 1725–76. [Google Scholar]
.(9) Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376:1417–27. [PubMed] [Google Scholar]
.(10) Yang L, Mao H, Yang R. Delays in referral, and parents refusing treatment for children with PKU. J Med Screen. 2011;18:214. [PubMed] [Google Scholar]
.(11)Chace DH, Millington DS, Terada N, Kahler SG, Roe CR, Hofman LF. Rapid diagnosis of phenylketonuria by quantitative analysis for phenylalanine and tyrosine in neonatal blood spots by tandem mass spectrometry. Clin Chem. 1993;39:66–71 [PubMed] [Google Scholar]

.(12) Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U. Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab. 2011;104(Suppl):S2–9. [PubMed] [Google Scholar]

.(13) Park J, Jang W, Chae H, Kim Y, Chi HY, Kim M, et al. Comparison of targeted next-generation and sanger sequencing for the BRCA1 and BRCA2 mutation screening. Ann Lab Med. 2016;36:197–201. [PMC free article] [PubMed] [Google Scholar]

.(14) Park J, Jang W, Chae H, Kim Y, Chi HY, Kim M, et al. Comparison of targeted next-generation and sanger sequencing for the BRCA1 and BRCA2 mutation screening. Ann Lab Med. 2016;36:197–201. [PMC free article] [PubMed] [Google Scholar]
Treatmentترقيم

Li, Qingshan, and Olof Kämpe. "Recombinant Phe-free proteins for use in the treatment of phenylketonuria." U.S. Patent No. 10,174,354. 8 Jan. 2019 (15).

NSPKU (National Society for Phenylketonuria). (2014). Management of phenylketonuria: a consensus document for the diagnosis and management of children, adolescents and adults with phenylketonuria (PKU). National Society for Phenylketonuria (UK) Ltd. http://www.nspku.org/. Accessed 1 June 2016\ (16).

Spécola, N., & Chiesa, A. (2017). Alternative therapies for PKU. Journal of Inborn Errors of Metabolism and Screening, 5, 2326409816685734(17).

http://scholar.google.com

Risk factor
Harris, Benjamin S. MD, MPH; Bishop, Katherine C. MD; Kemeny, Hanna R. BS; Walker, Jennifer S. MLS; Rhee, Eleanor MD; Kuller, Jeffrey A. MDRisk -Factors for Birth Defects: February 2017 - Volume 72 - Issue 2 - p 123–135